慢性乙型肝炎核苷(酸)类似物经治患者再治疗策略

陈士俊; 杜文军

慢性乙型肝炎核苷(酸)类似物经治患者再治疗策略

1. 山东大学附属传染病医院山东省肝病诊疗中心
2. 济南市传染病医院

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3839
- HTML全文浏览量: 11
- PDF下载量: 801
- 被引次数: 0
出版历程
- 收稿日期: 2011-08-30
- 出版日期: 2011-12-20

Re-treatment for relapsed patients after an initial nucleotide (s) analogue therapy in chronic hepatitis B

摘要

摘要: 核苷(酸)类似物在慢性乙型肝炎的临床治疗中的应用日益广泛,恰当处理核苷(酸)类似物经治患者的停药后复发及其再治疗、合理把握再治疗方案备受关注。核苷(酸)类似物经治患者可分为正在治疗和经治复发两大类。对于正在治疗的经治患者目前按照路线图的概念来进行管理;而对于经治复发的患者根据其初始治疗的不同应答情况可采用优化治疗及联合治疗的策略进行管理。
- 肝炎,乙型,慢性 /
- 核酸类,核苷酸类和核苷类 /
- 抗病毒药
Abstract: Nucleotide (s) analogues have been widely used in the treatment of chronic hepatitis B.It is important to deal with the relapsed patients treated with an initial nucleotide (s) analogues therapy properly, and grasp of re-treatment program reasonably.Patients treated with nucleotide (s) analogues can be divided into two categories: being treated and relapsed after treatment.The first group of patients should be managed by the concept of the road map meanwhile the latter should be depending on the initial treatment response of combination therapy which can be used to optimize the treatment and management strategies.
- hepatitisB /
- chronic /
- nucleic acids

HTML全文

参考文献(19)

[1]窦晓光, 张文宏.拉米夫定经治慢性乙型肝炎患者治疗策略专家研讨会纪要[J].肝脏, 2011, 16 (2) :58-59.

[2]Keeffe EB, Zeuzem S, Koff RS, et al.Report of aninterna-tional workshop:roadmap for management of patients receiv-ing oral therapy for chronic hepatitis B[J].Clin Gastroen-terol Hepatol, 2007, 5 (8) :890-897.

[3]Kurashige N, Ohkawa K, Hiramatsu N, et al.Lamivudine-to-entecavir switching treatment in type B chronic hepatitispatients without evidence of lamivudine resistance[J].JGastroenterol, 2009, 44 (8) :864-870.

[4] 庄辉.规范乙肝的抗病毒治疗[N].中国医学论坛报, 2010-06-03.

[5]Ha NB, Ha NB, Garcia RT, et al.Medication Nonadherencewith Long-Term Management of Patients with Hepatitis B eantigen-Negative Chronic Hepatitis B[J].Dig Dis Sci, 2011, 56 (8) :2423-2431.

[6]Chotiyaputta W, Lok AS.Endpoints of hepatitis B treatment[J].J Viral Hepat, 2010, 17 (10) :675-684.

[7]Zoulim F, Locarnini S.Hepatitis B virus resistance to nucleos (t) ide analogues[J].Gastroenterology, 2009, 137 (5) :1593-1608.

[8]Yoon SK, Jang JW, Kim CW, et al.Long-term results oflami-vudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B:Response and relapse rates, andfactors related to durability of HBeAg seroconversion[J].In-tervirology, 2005, 48 (6) :341-349.

[9]Chien RN, Liaw YF.Short term lamivudine therapy in activeHBeAg-negative chronic hepatitis B patients in Taiwan[J].Antivir Ther, 2006, 11 (7) :947-952.

[10]Fung SK, Wong F, Hussain M, et al.Sustained response af-ter a 2-year course of lamivudine treatment of hepatitis B eantigen-negative chronic hepatitis B[J].J Viral Hepat, 2004, 11 (5) :432-438.

[11]Wu IC, Shiffman ML, Tong MJ, et al.Sustained hepatitis Be antigen seroconversion in patients with chronic hepatitis Bafter adefovir dipivoxil treatment:analysis of precore andbasal core promotor mutants[J].Clin Infect Dis, 2008, 47 (10) :1305-1311.

[12]Gish RG, Lok AS, Chang TT, et al.Entecavir therapy for upto 96 weeks in patients with HBeAg-positive chronic hepati-tis B[J].Gastroenterology, 2007, 133 (5) :1437-1444.

[13]Lai CL, Shouval D, Lok AS, et al.Entecavir versus Lamivu-dine for Patients with HBeAg-Negative Chronic Hepatitis B[J].N Engl J Med, 2006, 354 (10) :1011-1020.

[14]Shin JW, Park NH, Park JH, et al.Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudinetherapy in HBeAg-positive chronic hepatitis B[J].J ViralHepat, 2005, 12 (4) :393-397.

[15] 李兰娟, 侯金林.核苷 (酸) 类药物联合治疗慢性乙型肝炎专家建议[J].中华临床感染病杂志, 2011, 4 (2) :65-68.

[16]Niro GA, Santantonio T, Fontana R, et al.Re-treatment ofpatients with anti-HBe-positive chronic hepatitis B who re-lapsed after an initial course of lamivudine[J].Aliment Phar-macol Ther, 2003, 18 (9) :933-940.

[17]Lok AS, McMahon BJ.AASLD Practice Guidelines:ChronicHepatitis B:Update 2009[J].Hepatology, 2009, 50:1-36.

[18]Reijnders JGP, Pas SD, Schutten M, et al.Entecavir showslimited efficacy in HbeAg-positive B patients with a partialvirologic response to adefovir therapy[J].J Hepatol, 2009, 50 (4) :674-683.

[19]Wang LC, Chen EQ, Cao J, et al.Combination of Lamivudi-ne and adefovir therapy in HBeAg-positive chronic hepatitisB patients with poor reaponse to adefovir monotherapy[J].J Viral Hepat, 2010, 17 (3) :178-184.

施引文献

资源附件(0)

访问统计